Dr Gill on the Efficacy and Genomic Features of Ropeginterferon Alfa-2B in Myelofibrosis

Harry Gill, MD, FRCP, FRCPath, discusses updated efficacy data and analysis of genomic characteristics for ropeginterferon alfa-2B in primary myelofibrosis.

Related Keywords

Hong Kong ,Harry Gill ,Li Ka Shing ,Dynamic International Prognostic Scoring System ,Hong Kong University Of Medicine ,Department Of Medicine ,Hong Kong University ,Dynamic International Prognostic Scoring ,Eha Congress ,D ,Orcp ,Rcpath ,Ct04988815 ,Ropeginterferon Alfa 2b ,Myelofibrosis ,